Study found that both adefovir dipivoxil and pegylated interferon alpha are beneficial for patients with chronic hepatitis B in terms of suppressing viral load, reducing liver damage-associated biochemical activity, inducing HBeAg seroconversion, and reducing liver fibrosis and necroinflammation